Neurology

Kriya adds neurology pipeline to gene therapy portfolio through Redpin Therapeutics acquisition

18-Nov-2022 By Rachel Arthur

Gene therapy company Kriya Therapeutics is acquiring Redpin Therapeutics, a privately held biotech developing regulatable gene therapies for intractable diseases of the nervous system.

Lonza to manufacture Alector’s mAb drug candidates for Ph I trial

09-May-2019 By Maggie Lynch

Lonza will provide manufacturing for Alector’s Phase I drug candidates for neurodegenerative diseases from its Switzerland site, which is expected to be operational by mid-2020.

Neurocrine agrees to pay up to $1.7bn in gene therapy collaboration

31-Jan-2019 By Maggie Lynch

Neurocrine and Voyager enter an agreement to fund and develop gene therapy candidates for the treatment of severe neurological diseases.

Selexis and Hoba collaborate on neuropathy pain treatment

09-Oct-2018 By Maggie Lynch

Selexis and Hoba Therapeutics have entered an agreement to advance Hoba’s clinical candidate for the treatment of peripheral neuropathic pain.